Combined Therapy with Peritoneal Dialysis and Hemodialysis in Japan: Current Status and Criteria for Initiation and Discontinuation
This study characterizes the current status of combined peritoneal and hemodialysis therapy in Japan, revealing that it is primarily initiated for fluid overload or inadequate dialysis based on objective metrics like Kt/V and β2-microglobulin, while highlighting the urgent need for evidence-based guidelines regarding its initiation and discontinuation to prevent complications such as encapsulating peritoneal sclerosis.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
When the kidneys fail completely, the body can no longer filter waste or remove excess fluid, a condition that requires artificial replacement to keep a person alive. One common method is peritoneal dialysis, where a special fluid is introduced into the belly to soak up toxins before being drained out. This approach offers a flexible schedule and often helps preserve the remaining natural function of the kidneys. However, over time, the lining of the belly can change, or the kidneys may stop working entirely, making the belly-based treatment less effective at clearing waste or managing fluid. When this happens, doctors must decide whether to switch the patient entirely to a machine-based treatment called hemodialysis, which filters blood outside the body, or to use a combination of both methods. In Japan, where patients often wait many years for a kidney transplant, this hybrid approach is a standard part of care, allowing people to stay on peritoneal dialysis longer while adding a weekly session of machine dialysis to fill the gaps.
A team of researchers in Japan recently set out to understand exactly how this combined therapy is being used in real-world clinics and what rules doctors follow when deciding to start or stop it. They wanted to move beyond general guidelines to see the actual habits of medical professionals across the country. To do this, they looked at two distinct sources of information. First, they examined a massive national database containing records from nearly two thousand patients currently receiving both types of dialysis. This gave them a clear picture of who these patients are, how long they have been on treatment, and what their daily lives look like. Second, they sent a detailed survey to hundreds of medical facilities that manage peritoneal dialysis, asking doctors directly about their decision-making processes. They wanted to know what specific signs, such as blood test results or physical symptoms, trigger the switch to combined therapy, and what factors lead them to stop the belly treatment entirely and move a patient to machine dialysis only.
The data revealed that the patients receiving this combined treatment are generally in good health. Most are around sixty-two years old, and nearly ninety percent are able to walk around and perform daily activities without significant trouble. The typical patient has been on dialysis for about four years. When it comes to the treatment itself, the vast majority receive their machine-based dialysis just once a week, usually on a single day, while continuing their daily belly treatments on the other days. The researchers found that the primary reason for adding the weekly machine session is that the belly treatment alone is no longer removing enough waste or fluid. Specifically, about forty-four percent of patients were switched because of fluid overload, where the body holds too much water, and another twenty-seven percent were switched because the dialysis was simply not cleaning the blood well enough. A smaller group faced both issues simultaneously.
When the doctors were asked what specific numbers or symptoms they look for to make these decisions, a clear pattern emerged. For checking if the dialysis is cleaning the blood effectively, physicians frequently rely on a measure called Kt/V, which tracks how much urea is removed, and the level of a substance called beta-2 microglobulin in the blood. The most common threshold for starting combined therapy is when the weekly Kt/V drops below 1.7 or when beta-2 microglobulin rises above 30 milligrams per liter. For fluid problems, doctors look at physical signs like swelling in the legs or shortness of breath, as well as blood markers that indicate the heart is under stress. Interestingly, the researchers noted that while these specific numbers are widely used, they are often based on experience rather than strict new scientific proof.
The study also explored when doctors decide to stop the peritoneal dialysis completely and move a patient to machine dialysis only. This decision is often driven by the need to prevent a serious complication called encapsulating peritoneal sclerosis, a condition where the belly lining becomes thick and scarred, trapping the intestines. The survey showed that doctors commonly use three main warning signs to trigger this switch: if the patient has been on peritoneal dialysis for ten years, if they have had three or more episodes of infection in the belly, or if tests show the belly lining has become too permeable. These rules of thumb are deeply embedded in Japanese medical practice, helping doctors balance the benefits of staying on peritoneal dialysis against the long-term risks of scarring.
Ultimately, the researchers concluded that while the combined therapy approach is well-established and widely used in Japan, the specific criteria for starting and stopping it are largely based on clinical experience and historical guidelines rather than fresh, large-scale evidence. The study highlighted that while doctors are successfully managing thousands of patients with this hybrid method, there is a need for more rigorous research to confirm the best thresholds for these decisions. By mapping out the current landscape, the authors hope to encourage further investigation that will lead to more precise, evidence-based guidelines for the future, ensuring that patients receive the most effective care possible as they navigate the long journey of kidney failure.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.